Thirteen‐year genomic analysis (2010–2022) reveals high‐risk ICU Pseudomonas aeruginosa in China
mLife · 2026-08 · 5 (4) · 459-472
DOI: 10.1002/mlf2.70097 ↗Kurz gefasst
Fachartikel in der Zeitschrift mLife, online erschienen am 27.08.2026. Verfasst von Jiadai Huang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou China. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province, National Natural Science Foundation of China, Health and Medical Research Fund.
Abstract (Originalsprache)
Pseudomonas aeruginosa is a significant opportunistic pathogen, particularly prevalent in intensive care units (ICUs). Through a comprehensive genomic and phenotypic analysis of 518 ICU and healthy isolates collected over a 13‐year period (2010–2022), we found that ICU strains, despite reduced sequence type (ST) diversity, are dominated by persistent high‐risk clones, notably ST463 and ST1076. Despite possessing a lower overall prophage content, ICU isolates show a broader and more diverse repertoire of anti‐phage defense systems. This strengthened defense capacity correlates with ICU strains, demonstrating heightened resistance to phage challenge and contributing to lower historical phage exposure. Concurrently, ICU isolates harbor a significantly higher antimicrobial resistance (AMR) gene burden. Our detailed genomic analysis shows that this increased AMR is primarily driven by plasmid acquisition. Importantly, AMR genes associated with prophage elements are exclusively found in ICU isolates, highlighting their selective retention and functional contribution to resistance in this high‐pressure environment. Furthermore, specific virulence genes, including exoU , pilA , and rhsP2 , are more prevalent in ICU strains, indicating enhanced pathogenicity. Collectively, these findings underscore a qualitative distinction in ICU P. aeruginosa : their dominance and persistence stem from highly adapted clones, robust anti‐phage defenses, rapid plasmid‐mediated AMR acquisition, and clinically selected prophage‐borne AMR.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou China.
- Department of Biomedical Sciences, College of Biomedicine City University of Hong Kong Hong Kong China.
- Shenzhen Research Institute City University of Hong Kong Shenzhen China.
- State Key Lab for Chemical Biology and Drug Discover and the Department of Food Science and Nutrition, Faculty of Science The Hong Kong Polytechnic University Hong Kong China.
ORCID-Profile: Jiadai Huang
Förderung
- Natural Science Foundation of Zhejiang Province
- National Natural Science Foundation of China
- Health and Medical Research Fund
Zitieren
APA
Huang, J., Chen, K., Xie, M., Shen, W., Ju, X., Wu, Y., Li, J., Zhou, H., Huang, Y., Zhang, Y., Zhang, Y., Li, T., Xu, L., Sun, Y., Chen, F., Chen, S., Deng, X., Zhang, R., & Hu, Y. (2026). Thirteen‐year genomic analysis (2010–2022) reveals high‐risk ICU Pseudomonas aeruginosa in China. mLife, 5(4), 459-472. https://doi.org/10.1002/mlf2.70097
Vancouver
Huang J, Chen K, Xie M, Shen W, Ju X, Wu Y, et al. Thirteen‐year genomic analysis (2010–2022) reveals high‐risk ICU Pseudomonas aeruginosa in China. mLife. 2026;5(4):459-472. doi:10.1002/mlf2.70097
BibTeX
@article{Huang2026,
author = {Huang, Jiadai and Chen, Kaichao and Xie, Miaomiao and Shen, Weiyi and Ju, Xiaoyang and Wu, Yuchen and Li, Jiaping and Zhou, Hongwei and Huang, Yonglu and Zhang, Yizhou and Zhang, Yuanfeng and Li, Tianmin and Xu, Letong and Sun, Yue and Chen, Fang and Chen, Sheng and Deng, Xin and Zhang, Rong and Hu, Yanyan},
title = {Thirteen‐year genomic analysis (2010–2022) reveals high‐risk ICU Pseudomonas aeruginosa in China},
journal = {mLife},
year = {2026},
volume = {5},
number = {4},
pages = {459--472},
doi = {10.1002/mlf2.70097}
}
EUVIMED